文献リスト

1) Pritchard JB, Miller DS. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev. 1993; 73: 765-96

2) Enomoto A, Takeda M, Tojo A, et al. Roles of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002; 13: 1711-20

3) Enomoto A, Takeda M, Taki K, et al. Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Phramacol. 2003; 466: 3-20

4) Deguch T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002; 61: 1760-8

5) Deguchi T, Kusuhara H, Takadate A, et al. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004; 65: 162-74

6) Mikkaishi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004; 101: 3569-74

7) Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol. 2009; 20: 2546-55

8) Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004; 447: 666-76

9) Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family- Biopharmaceutical, physiological, and pathological roles. Parhmaceutical Res. 2007; 24: 450-70

10) Mikkaichi T, Suzuki T, Tanemoto M. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004; 19: 171-9

11) Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP-SLC21 family- phylogenetic classification as OATP-SLCO superfamily, new nomenclature and molecular functional properties. Pflugers Arch. 2004; 447: 653-65

12) Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol. 2006; 290: F251-61

13) Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000; 58: 944-58

14) Laouari D, Yang R, Veau C, et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Pysiol. 2001; 280: F636-45

15) Smeets PHE, van Aubel RAMH, Wouterse AC, et al. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004; 15: 2828-35

16) van Aubel RAMH, Smeets PHE, Peters JGP, et al. The MRP4(ABCC4) gene encodes a novel apical organic anion transporter in human kidney proximal tubules- putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002; 13: 595-603

17) Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev. 2004; 84: 987-1049

18) Sweet DH, Bush KT, Nigam SK. The organic anion transporter family- from physiology to ontogeny and the clinic. Am J Physiol Renal Physiol. 2001; 281: F197-205

19) van de Water FM, Masereeuw R, Russel FGM. Fuction and regulation of multidrug resistance proteins(MRPs) in the renal elimination of organic anions. Drug Metb Rev. 2005; 37: 443-71

20) Anzai N, Kanai Y, Endou H. Organic anion transporter family- Current knowledge. J Phramcol Sci. 2006; 100: 411-26

21) Motohashi H. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soci Nephrol. 2002; 13: 866-74

22) Sekine T, Cha SH, Tsuda M, et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998; 429: 179-81

23) Enomoto A, Takeda M, Shimoda M, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J pharmacol Exp Ther. 2002; 301: 797-802

24) Kusuhara H, Sekine T, Utsunomiya-Tate N, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999; 274: 13675-90

25) Cha SH. Sekine T, Kusuhara H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000; 275: 4507-12

26) Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002; 417: 447-52

27) Ekarantanawong S, Anzai N, Jutbaha P, et al. Human organic anion transporter 4 is a renal apical organic anion/decarboylate exchanger in the proximal tubules. J Phramacol Sci. 2004; 94: 297-304

28) Youngblood GL, Sweet DH. Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Pphysiol Renal Physiol. 2004; 287: F236-44

29) Anzai N, Jutabha P, Enomoto A, et al. Functional characterization of rat organic anion transporter 5 (Slc22a19) at the apical membrane of renal proximal tubules. J Phramacol Exp Ther. 2005; 315: 534-44

30) Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9: 195-205

31) Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol. 2007; 19: 151-7

32) Vanholder R, Smmet RD, Glorieux G, et al. Review on uremic toxins- Classification, concentration, and interindividual variability. Kidney Int. 2003; 63: 1934-43

33) Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: A new focus on an old subject. Semin Dial. 2005; 18: 203-11

34) Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of urenic toxins. J Am Soc Nephrol. 2008; 19: 863-70

35) Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity？ Periatr Nephrol. 2008; 23: 1211-21

36) Niwa T. Renal cell metabolism. In: Massry SG, Glassock RJ, editors. Textbool of Nephrology. 4th ed. Philadelphia: Williams and Wilkins; 2001. p.1269-72

37) Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994; 124: 96-104

38) Miyazaki T, Aoyama I, Ise M, et al. An oral sorbent reduces overload of indoxyl sulfate and gene expression of TGF-β1 in uraemic rat kidneys. Nephrol Dial Transplant. 2000; 15: 1773-81

39) Enomoto A, Niwa T. Roles of organic anion transporters in the progression of chronic renal failure. Therapeu Apheresis Dial. 2007; 11: S27-31

40) Sun H, Frasseto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Theraputics. 2006; 109: 1-11

41) Saito H. Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury-Pharmacological and toxicological implications. Pharmacol Ther. 2010; 125: 79-91

42) Deguchi T, Takemoto M, Uehara N, et al. Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J Pharamacol Exp Ther. 2005; 14: 932-8

43) Matsuzaki T, Watanabe H, Yoshitome K, et al. Down regulation of organic anion transporters in rat kidney under ischemia reperfusion -induced acute renal failure. Kidney Int. 2007; 71: 539-47

44) Schneider R, Sauvant C, Betz B, et al. Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats. Am J Physiol Renal Physiol. 2007; 292: F1599-605

45) Morisaki T Matsuzaki T, Yokoo K, et al. Regulation of renal organioc ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm Res. 2008; 25: 2526-33

46) Aleksunes LM, Augstine LM, Scheffer GL, et al. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology. 2008; 250: 82-8

47) Sakurai Y, Motohashi H, Ueo H, et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004; 21: 61-7

48) Sakurai Y, Motohashi H, Ogasawara K, et al. Pharmacokinetic siginificance of renal OAT3(SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res. 2005; 22: 2016-22

49) Suzuki T, Abe T. Thyroid hormone transporters in the brain. Cereberum. 2008; 7: 75-83

50) Abe T, Suzuki T, Unno M, et al. Thyroid hormone transporters: recent advances. Trends Endocrinol Metab. 2002; 13: 215-20

51) Soga T, Ohashi Y, Naraoka H, et al. Quantitative metabolome analysis using capillary electrophoresis mass soectrometry. J Proteome Res. 2003; 2: 488-94

52) Ueda S. Yamagishi S, Matsumoto Y, et al. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol. 2007; 11: 115-21

53) Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential taraget for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2008; 17: 609-15

54) Taes YE, Marescau B, De Vriese A, et al. Guanidino compounds after creatine supplementation in renal failure paitents and their relation to inflammatory status. Nephrol Dial Transplat. 2008; 23: 1330-5

55) De Deyn PP, Vanholder R, Eloot S, et al. Guanidino compounds as uremic (neuro)toxins. Semin Dial. 2009; 22: 340-5

56) Saffran M, Prado JL. Inhibition of aconitase by trans-aconitate. J Biol Chem. 1949; 180: 1301-9

57) Toyohara T, Akiyama Y, Suzuki T, et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res. 2010; 33: 944-52

58) Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and Cocckcroft and Gault fomula for the estimation of glomernlar filtration rate. Nephrol Dial Transplant. 2003; 18: 2024-31

59) Fujii-Kuriyama Y, Miura J. Molecular mechanism of AhR functions in the regulation of cytochrome P450 genes. Biophys Res Commun. 2005; 228: 311-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp